Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On February 5, 2018, Alexion Pharmaceuticals filed an
application for leave to appeal a decision of the Federal Court of
Appeal (FCA) dismissing its challenge to the constitutionality of
certain of the Patented Medicine Prices Review Board (PMPRB)
provisions of the Patent Act: SCC Case No. 37949. The FCA decision,
Alexion Pharmaceuticals Inc v Canada (Attorney General),
2017 FCA 241, was previously reported
here
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
